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Abstract
Background: We utilized our previous studies analyzing the reforms affecting the health sector developed in the
1990s by financial groups to frame the strategies implemented by the pharmaceutical industry to regain market
positions and to understand the challenges that regulatory agencies are confronting.
Methods: We followed an analytical approach for analyzing the process generated by the disputes between the
financial groups and the pharmaceutical corporations and the challenges created to governmental regulation. We
analyzed primary and secondary sources using situational and discourse analyses. We introduced the concepts of
biomedicalization and biopedagogy, which allowed us to analyze how medicalization was radicalized.
Results: In the 1990s, structural adjustment policies facilitated health reforms that allowed the entrance of
multinational financial capital into publicly-financed and employer-based insurance. This model operated in
contraposition to the interests of the medical industrial complex, which since the middle of the 1990s had
developed silent reforms to regain authority in defining the health-ill-care model. These silent reforms radicalized
the medicalization. Some reforms took place through deregulatory processes, such as allowing direct-to-consumer
advertisements of prescription drugs in the United States. In other countries different strategies were facilitated by
the lack of regulation of other media such as the internet. The pharmaceutical industry also has had a role in
changing disease definitions, rebranding others, creating new ones, and pressuring for approval of treatments to
be paid by public, employer, and private plans. In recent years in Brazil there has been a substantial increase in the
number of judicial claims demanding that public administrations pay for new treatments.
Conclusions: We found that the dispute for the hegemony of the health sector between financial and
pharmaceutical companies has deeply transformed the sector. Patients converted into consumers are exposed to
the biomedicalization of their lives helped by the biopedagogies, which using subtle mechanisms present
discourses as if they are objective and created to empower consumers. The analysis of judicialization of health
policies in Brazil could help to understand the complexity of the problem and to develop democratic mechanisms
to improve the regulation of the health sector.
Background
As we demonstrated in our previous study the worldwide
domain of financial capital, which has been increasing
since the middle of the 1970s, defined the reforms of the
health sector in the decades that followed [1-5]. Insurance
companies and administrators of mutual and pension
funds expanded their business opportunities by not only
moving into different countries but by also entering into
new economic sectors, such as health. At the end of the
1980s and beginning of the 1990s the flows of financial
capital into the health sector increased exponentially [1].
This process occurred first in the U.S. and after in many
developed and developing countries, introducing new
social actors, new rules, and new insurance models that
have direct impact on the management and provision of
health care services. Insurance companies had operated in
the health sector before, but their operations were limited
to selling life insurance policies and health insurance
plans, mostly to individuals. The radical financialization of
the world economy in the 1990s, supported by U.S. poli-
cies that deregulated the financial markets, opened the
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doors for corporate groups to intensify their operations
worldwide using new non-regulated financial tools [6].
During the late 1980s and 1990s, pharmaceutical com-
panies and health professionals were impacted by the
managed care model of containing costs. The increased
hegemony of financial capital in the health sector
required changes in the way that business was con-
ducted. The business model traditionally followed by
health providers and the producers of drugs, devices,
and equipment depends upon increasing consumption
of health services and treatments. The pharmaceutical
industry focused on health professionals, especially phy-
sicians, to create or increase the demand for its pro-
ducts. The financial groups administrating private,
public, and employer-sponsored health plans have an
opposite model. These companies realize more profits
by cutting access to services and treatments, especially
the more costly ones. For this reason, managed care
organizations developed strategies to control costs using
administrative procedures to limit physicians’ prescrip-
tions and referrals.
At the beginning of the 1990’s, financial groups oper-
ating in the health sector introduced explicit and silent
reforms following the U.S. model of managed care in
several countries in Latin America, Asia, and Europe [2].
By silent reforms we mean changes in rules related to
the health sector operation and/or conceptualization
that most of the time avoids the legislative process and
moreover, the public debate [3].
In Latin America and other developing countries,
structural adjustment policies and neoliberal ideology
created the context for health reforms that allowed the
entrance of multinational financial companies into pub-
licly financed programs and employer-based insurance
[4,5]. Later, financial capital entered into the manage-
ment of health care services: hospitals, home care, long-
term care, nursing homes, etc. [7].
In the health sector the massive entrance of financial
capital changed not only the modus operandi at the eco-
nomic level but also the common sense regarding the
ideas about health-ill-care. By common sense we refer
to core ideas that underlie discourses on health in a spe-
cific time and society. Common sense is shared meaning
that provide direction for society, and act as social
cement that fills gaps and artificially softens social con-
tradictions. Common sense shapes the subjective assess-
ment of a shared situation by people in different places
in the social structure (p. 55) [3]. Cost containment,
individual responsibility, cost-effectiveness, case manage-
ment of patients, coordination of care, etc. are technical
concepts that penetrated the sector and deeply trans-
formed the conceptualization of health-ill-care. Profes-
sional decisions were subordinated to administrative
procedures which focused on maximizing profits
masked most of the times as decisions based on scienti-
fic evidence.
From our previous study it was clear that the adminis-
trative model implemented by the financial groups con-
trolled expenditures limiting access to health services
operating in contraposition to the interests of the medical
industrial complex. The next step in our research agenda
was to understand if the most powerful group of the
medical industrial complex, the pharmaceutical industry,
has remained quiet while the corporate groups managing
financial capital were increasing their shares of the health
market. We observed that as a consequence of the mas-
sive adoption of managed care in the U.S. and other
countries, the pharmaceutical arm of the medical indus-
trial complex has developed health reforms, most of
them without public debate, to regain market share and
authority in defining the health-ill-care model [8]. These
silent reforms radicalized the medicalization, now defined
by some authors as biomedicalization [9]. Some reforms
took place through deregulatory processes such as weak-
ening the regulation regarding direct-to-consumer adver-
tisements of prescription drugs in the United States.
Others were developed more silently. This was the case
of the hidden role, through paid experts, that the phar-
maceutical industry has had in changing disease defini-
tions, developing clinical guidelines for diagnosing new
diseases or overdiagnosing others, and pressuring for
approval of treatments to be paid by public systems and
employer-based and private insurances. However, the
most successful strategies were focused on converting
patients into consumers.
In other countries, different strategies are facilitated by
the lack of regulation of other media instruments, such
as the internet. Disease campaign awareness and funding
of medical scientific and educational activities are also
used to hide the promotion of drugs. In recent years we
have observed in Brazil a substantial increase in the
number of judicial claims demanding that private insur-
ance and public administrations pay for non-approved
treatments, including the experimental ones. This could
be a strategy to regain market power in countries with
health care systems led by public administrations, not
driven by the market. These strategies could have ser-
ious consequences for the regulatory process of the
health sector.
The article will first present the strategies utilized by
the pharmaceutical industry to regain market leadership
in the United States. We consider it important to ana-
lyze the changes operating in this country because the
U.S. medical model influences the conceptualization and
practice of medicine in the rest of the world, especially
in developing countries. Second, we will analyze some
contributions from the social sciences that allow a better
comprehension of the phenomenon of the creation of
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the health consumer as part of the biomedicalization led
by the medical industrial complex. Finally, we will intro-
duce the research that our team is conducting in Brazil
analyzing if the judicial mandates obligating the public
health system to financially cover new treatments are
part of the strategies of the pharmaceutical industry to
create the health consumer and the impact that the
mandates have on the regulation of the health sector.
Methods
The study followed an analytical approach that reinter-
prets studies developed by other authors regarding the
reforms that the pharmaceutical industry has developed
during the past 20 years. The results of our study about
the managed care reforms provided the knowledge that
the financial groups developed strategies to control pro-
viders of health care services in order to decrease expen-
ditures. The study analyzed the ideological mechanisms
and the practices developed by financial groups and
other central actors in the health sector to change com-
mon sense about the conceptualization of health-ill-care,
including the idea that patients/users should be trans-
formed into consumers/clients [4]. In the light of these
processes, new questions arose: will the medical indus-
trial complex, and particularly the pharmaceutical cor-
porations, counter attack these reforms to regain market
power and hegemony in defining the medical model?
What kind of strategies will they implement if their tra-
ditionally targeted groups (health care providers) were
controlled by the strategies of the managed care groups?
To respond to these questions we used theoretical
concepts and research methods in the Foucaultian
meaning of “toolboxes” [10]. This resulted in the utiliza-
tion of theoretical concepts and research methods from
different authors, and not unique approaches with the
pretension to produce completed explanations about
the analyzed situation. We looked for concepts with the
potential to discover new interpretations and new dis-
courses. In this direction, we utilized some concepts
that proved their analytical power in other studies that
we conducted, such as common sense and silent
reforms. We found new ones, especially biomedicaliza-
tion and biopedagogies, which we considered have the
potential to bring new meanings to the analyzed
situation.
Several methodological approaches were useful for
creating a dialog between different sources of data. We
will mention two as the most important to our study: a)
situational analysis that provides elements to map differ-
ent discourses and, b) discourse analysis which we used
as a deconstructive reading and interpretation of power
relationships to gain a comprehensive understanding of
the effects of these dynamics in creating new subjectiv-
ities [10,11]. We are not trying to provide unequivocal
answers, but to reinterpret some strategies by connect-
ing different processes that appear disconnected in the
discourses elaborated by the two most powerful groups
operating in the health sector -the medical industrial
complex and the financial groups. We understand
power as multiple forces operating in a specific situation
and time. Power is related to the concept of governabil-
ity in the meaning of forces operating strategically to
structure new subjectivities [12].
The fundamental idea was to understand what the
pharmaceutical industry was doing to counter attack the
advances of the financial groups. To initiate the research
process we followed Rabinow’s idea of utilizing a tradi-
tional ethnographic method “to describe what is going
on” (p. 236) [12]. As a first step, we defined the macro
situation as the intercapitalistic disputes between the
medical industrial complex and the financial groups
operating in the health sector for increasing the share of
the market and defining the medical model. At meso
level we were interested in understanding if pharmaceu-
tical groups were developing strategies to change regula-
tions to impact the organization of the health sector. At
micro level we wanted to learn if the pharmaceutical
industry was also creating some mechanisms to recap-
ture the supply side of the health care sector equation
and/or developing mechanisms to capture the demand
side (patients/users).
We developed a non-systematic data collection and
analysis following the ethnographic method of observing
and analyzing data/information to widely describe the
situation [12]. Following Clarke, we can define our study
as a multisite/multiscape research, in the meaning that
we examined multiple kinds of data from a particular
situation of inquiry (p. 165) [11]. We utilize data from
different sources, such as articles, news, or other data
from list servers, materials researched for our teaching
and other research activities, as well as, data and new
insights of the situation gather by participating in
national and international forums related to health sec-
tor reforms. The initial materials gathered opened other
pathways to obtain additional data, such as references to
articles, names of companies, and individual and collec-
tive social actors involved in the situation, and descrip-
tion of regulations, among others. In addition, we
cannot deny that our personal experiences receiving
information as consumers from pharmaceuticals were
also an important source of data and inquiry. As
researchers we are part of the situation as subjects that
produce discourses about the situation, but also sub-
jected to discourses that others produce [13].
The extensive preliminary analysis allowed us to
notice that pharmaceuticals were turning to their favor
the strategy initiated by managed care organizations of
transforming patients/users into clients/consumers.
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From the preliminary analyses we also understood that
the pharmaceutical industry was taking part in a silent
process of health reforms to regain market power that
impact different levels: policy, economic, ideological,
and social. In addition, the team was interested in
understanding how the process operates at macro,
meso, and micro levels. The separation into these levels
had only methodological purposes; the process is intri-
cate and operates most of the times simultaneously at
all levels. We decided that the line of analysis that will
allow a wide and deep comprehension of the process
will be through the utilization of analytical categories
that capture the reforms that pharmaceutical companies
were involved in and benefit from. The broad categories
that we defined were changes in regulations, changes in
defining, branding and overdiagnosing diseases, and
mechanisms utilized to capture the demand side. Com-
plementing this process, part of our team started a lit-
erature review to describe the increasing involvement of
the judicial branch in the regulatory process in the
health sector in Brazil.
Using these categories, we developed a systematic lit-
erature and document review to find the data (primary
and secondary) that describes changes in regulations
and scientific norms, and in business models consistent
with the creation of health consumers. With the docu-
ments identified from different sources (academic arti-
cles, books, brochures, websites of professional, patient
and consumer associations, adds and news in television,
magazines, and newspapers, among others), we initiated
a process of mapping the information obtained in each
category from different sources to describe the situation
and the results of the changes in creating the health
consumer and radicalizing the medicalization. We fol-
lowed the procedures described by Clarke and we
recommend her book to learn about the operational
steps that we will not present here because an in-depth
explanation of these complex methods merit a separate
article [11].
The result of the process was the analytical descrip-
tion of selected strategies implemented by the pharma-
ceutical industry and their reinterpretation applying the
theoretical concepts of biomedicalization and biopeda-
gogies. This reinterpretation allows us to increase the
understanding of the effects that the discourses cur-
rently modeling the health sector have in creating new
subjectivities and biosocialities, some of them as part of
the hegemonic discourse and others questioning it.
The study contributes to the field of health policy by
highlighting how silent reforms introduced first by
financial companies and after by the medical industrial
complex, are challenging the regulation of the health
sector. The described analytical approach allowed us to
reinterpret the situation and show the need for further
study of the hidden processes and social actors that
could be behind the judicialization of the health sector
in countries were health is considered a common good
not a commodity.
Results
The medical industrial complex: strategies to regain
market leadership
To revitalize its role in the health sector the pharmaceu-
tical industry needed to find new strategies [14]. The
strategies were selected to create a new disease/ill/care
model, make drugs for healthy people, and to exploit
the idea developed by managed care organizations to
convert users/patients into clients/consumers [15]. In
order to accomplish these goals, the industry has been
successfully lobbying for regulatory changes and in
developing strategies to change the common sense
related to the conceptualization of health-ill-care. We
will analyze some of these changes and strategies in the
following sections.
Changes in regulations
As a first step in converting patients/users into clients/
consumers, the pharmaceutical industry required some
changes at the regulatory level. Several laws and modifi-
cations of existing regulations were approved in the U.S.
that facilitated the transformation of the business model
of pharmaceutical companies. For this article we will
consider two important regulatory changes, one that
facilitated the increase of the number of pharmaceutical
products in the market, and another that enhanced the
ability of the companies to offer the products to consu-
mers. The first one is the act that introduced user fees
to be paid by pharmaceutical companies to the Food
and Drug Administration (FDA) to initiate the approval
process for new drugs. The second one is related to the
changes introduced on the regulation of the direct-to-
consumer advertisements.
Introducing user fees for drug approvals In 1992, the
U.S. Congress approved the Prescription Drug User Fee
Act (PDUFA) with relatively little public debate [14].
The Act allowed pharmaceutical companies to pay fees
to speed the approval process and the FDA the ability
to use these fees to finance the specific areas. After the
Act was launched, new approvals were being issued in
unprecedented numbers and review times were at his-
toric lows. Important new drugs for cancer, AIDS, heart
diseases, and stroke were approved using this process,
benefiting many patients. But also numerous new drugs
for chronic diseases, mental health and lifestyle condi-
tions, some of them not very useful or really new and
sometimes dangerous, were approved, opening a new
dimension for the pharmaceutical business. According
to Angell, in 2002 the FDA approved 78 drugs. From
those only 17 contained new active ingredients and just
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seven were classified by the agency as improvements
over existing drugs (p. 16-17) [16]. The speedy process
established in the U.S. determined that many pharma-
ceutical companies chose this country for the introduc-
tion of new drugs into the market more than any other
country in the world.
The approval of this Act has also had consequences in
other countries. The most important consequence was
that in 1990s the World Bank (WB) and the Inter-
American Development Bank (IADB) promoted, in sev-
eral Latin American countries, the creation of regulatory
agencies following the FDA model, especially the user
fee provision. The reasoning of the WB and IADB was
that the user fees will counter the fiscal deficit by gener-
ating revenues to finance the new governmental agen-
cies. Additionally, according to these international
lending agencies, the efficiency of the bureaucratic pro-
cess of drug approval will be improved. Argentina
(1993) and Brazil (1999) created the agencies to regulate
drugs, foods, and medical technologies following the
FDA model of charging pharmaceutical companies fees
to initiate an approval process [17,18].
Changing the rules for advertising drugs The new reg-
ulation speeding the approval process increased the
amount of pharmaceutical products in the market, but
additional strategies were required to increase the
demand of the products. The capture of the supply side
(providers) of the health care equation developed by
managed care organizations, mobilized pharmaceutical
companies to develop strategies to capture the demand
side. The industry envisioned the idea to convert
patients into consumers with the right to be informed
about pharmaceutical products as they have the right to
receive information about other goods and services [14].
For years medical associations and also pharmaceutical
executives opposed direct-to-consumer advertisements
(DTCA) of prescription drugs, arguing that it will inter-
fere in the physician-patient relationship. But during the
1980s the increasing power of consumer organizations
created the possibility of advertisements as a way to
empower patients [14]. This idea was captured by the
managed care industry to promote the concept that an
informed patient could make rational decisions about
their health needs and not be manipulated by prescribers.
Using this concept, innovators within the pharmaceutical
industry convinced those who initially questioned that
the DTCA of prescription drugs was a way to empower
patients. Also, they promoted the idea that the DTCA
will create more awareness about diseases and conditions
not well known, but which were silently affecting huge
number of people.
DTCA already was approved and regulated by the
FDA, but the requirements were that the advertisements
must present the entire list of side effects and cautions,
limiting the power of the promotion by scaring the pub-
lic. In 1997, the FDA rolled back this requirement and
it opened the way for a new era in DTCA [16]. Compa-
nies increased exponentially the amount of DTCA. In
2001, the big companies spent $1.8 billion in DTCA,
but in 2003 they spent $3 billion [14]. The regulatory
capacity of the agency is almost null to control this
increased amount of advertisements, especially if we
consider that in 2001 drug companies also substantially
increased the ads in newspapers and magazines, exceed-
ing largely the number of ads in medical journals for
that year. Drug companies are required by law to have
their DTCA reviewed by the FDA when they launch a
new campaign. However in 2001, the agency had only
30 reviewers to control 34,000 DTCA. In addition, the
agency cannot verify whether the companies submit all
the ads [19].
Most of the DTCA are for chronic and lifestyle condi-
tions, as well as behavioral/mental health problems. The
ads will train consumers about signs and symptoms, as
well as brand name medications, and direct them to
consult with their physicians. Perhaps, it would be more
appropriate to say, to convince their physicians about
the diagnosis and treatment. These advertisements are
now the biggest investment of pharmaceutical compa-
nies in marketing and include ads in television, radio,
magazines, internet, and mail advertisements, among
others. But more than providing useful information to
patients for specific health problems, the ads market the
diseases/conditions (old, new, and rebranded) for which
the pharmaceuticals have drugs to sell. The idea, pro-
moted by the new pharmaceutical paradigm, is not just
to sell pills to cure diseases, but to create a state of fear
of becoming sick, aging, and dying [15,20].
In other countries, pharmaceutical companies are
pressuring regulators to allow DTCA for prescription
drugs and to modify the classification of some drugs to
be sold over-the-counter. While drug companies are
waiting for regulation changes, they are using other stra-
tegies to reach consumers, such as media disease aware-
ness campaigns, promotion of drugs presented as news
in television and other media, and developing health
teaching materials for schools, among others. The cen-
tral idea is to increase the capacity of consumers to self-
diagnose and self-prescribe [21,22].
Changing health definitions, branding diseases and
overdiagnosing others
Since the middle 1990s, pharmaceutical companies have
had more influence within the expert committees
reviewing disease/condition definitions and describing
new diseases and health risks to be covered by private,
employer-based, and public insurance plans [16]. The
majority of these changes are defined by medical specia-
lists in committees organized by official agencies,
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professional organizations, and international institutions,
like the World Health Organization (WHO). Most of
the time, the decisions of these bodies of experts, pre-
sented as based on scientific research, are adopted
worldwide.
In middle 1990s, committees of experts redefined sev-
eral diseases/conditions and health risks. These commit-
tees decreased the parameters for high blood pressure
and defined prehypertension; decreased the level of fast-
ing glucose to define diabetes mellitus and of serum
cholesterol for hypercholesterolemia; also experts
decreased the Body Mass Index values for being over-
weight and obese [16,23]. In the U.S., these changes
resulted in the following increases in potential cases:
14% for diabetes; 35% for hypertension; 86% for
hypercholesterolemia, and 42% for overweight. This
opened the possibility for 140,630,000 additional indivi-
duals to be diagnosed with some of these diseases/con-
ditions and treated with drugs and other medical
interventions [23].
This is a dangerous approach that implies moving the
bell curve of a population to the left in order to capture
more people with low risk to prevent them from devel-
oping the disease/condition. While this approach may
be useful for preventing exposure to hazards, such as
tobacco or contaminants, to use this approach for iden-
tifying people at risk for conditions that require medica-
tions creates a potentially dangerous situation exposing
healthy people to adverse effects of drugs [24]. The idea
of health promotion has been deeply medicalized
because healthy behaviors are now related to the capa-
city of individuals to control their risk of becoming sick.
The social, economic, and political factors that create
health risks and diseases are denied under the renewed
logic of a positivist science. This logic reinstalled biolo-
gical factors as the central causes for diseases, and medi-
cal procedures and individual behavior changes as the
only way to cure or alleviate them.
The described changes in definitions of diseases/con-
ditions were not the only targets of pharmaceutical
companies. These companies moved from promoting
drugs to treating diseases, to promoting diseases/condi-
tions to fit their drugs. During the 1980s and 1990s
companies in the U.S. started promoting lifestyle drugs,
including those for cosmetic and sexual enhancement.
The crossover to curative medicine occurred with psy-
chotropic drugs that have a wide range of active proper-
ties, allowing pharmaceutical companies to expand the
spectrum of diseases/conditions for which the drugs
could be promoted. As Applbaum explains,
“one class of antidepressants, the specific serotonin
reuptake inhibitors, is marketed for eight distinct
psychiatric conditions ranging from social anxiety
disorder to obsessive-compulsive disorder to pre-
menstrual dysphoric disorder. And ‘lifestyle market-
ing’ has now extended to the promotion of many
blockbuster ‘maintenance drugs’ intended for daily,
lifelong consumption, such as drugs for allergies,
insomnia, and acid reflux disease” (p. e189) [25].
Previously, acid reflux was known simply as heartburn
and treated with a glass of milk or an over-the-counter
antiacid. In the 1990s in the U.S., Glaxo began promot-
ing one of its drugs to treat heartburn under a new
name, GERD (gastroesophageal reflux disease), and
described it as having serious health consequences if not
treated (p. 86) [16].
Social phobia disorder, which is a very rare condition,
was renamed social anxiety disorder by SmithKline just
after September 11, 2001. The company launched an
ambitious campaign promoting its antidepressant Paxil
for this use. The commercial showed images of the
World Trade Center towers collapsing (p. 88) [16]. Cor-
porations are branding social, cultural, and political
situations as diseases, defining them as conditions that
could be medicated. The list is long and includes atten-
tion deficit disorder, not only in children but now also
in adults, depression, erectile dysfunction, female sexual
dysfunction, bipolar disorder, restless legs, social anxiety,
and panic attack, among many others.
In addition to their promotional efforts to create pub-
lic awareness of new and old diseases/conditions, phar-
maceutical companies create short questionnaires to test
the risk for diseases/conditions. These questionnaires
are extensively utilized in primary care settings by physi-
cians, physician assistants, and nurse practitioners, espe-
cially for diagnosing mental health problems for which
they are not very well trained to diagnose. Using these
tools, non-specialized professionals feel confident about
their diagnoses and their capacity to medicate adults
and children with psychiatric drugs. The strategies
implemented by pharmaceutical companies successfully
expanded the market through increasing the amount of
professionals diagnosing and prescribing. This strategy,
together with the increased investments in directed-to-
consumer marketing generated the results for which
they were developed. The top 25 drugs directly mar-
keted to consumers in the U.S. rose by 34% from 1998
to 1999, while other prescriptions rose only 5.1% [9].
Capturing the demand side
Another strategy that pharmaceutical companies uti-
lized, initially in the U.S., to regain market positions was
to support patients and consumer associations. The
pharmaceutical groups learned from the women’s health
movements and AIDS patient groups how valuable
advocates could be for demanding increases for research
funds, the approval of new drugs, and the coverage of
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new treatments by public programs, and employer-based
and private health plans [9].
Pharmaceutical companies targeted patient and consu-
mer organizations offering funds to help them to create
awareness of diseases/conditions in the general public
and among policymakers [14]. Education was the new
strategy to a) pressure health plans to pay for costly
drugs, especially new drugs or off-label indications of
approved ones, most of the time with not much more
benefit than the older ones but more expensive; b) dis-
credit some treatments, such as psychotherapies, as
costly and not as efficacious as new drugs for treating
mental health disorders; and c) convince health plans
about the improvement outcomes of some drugs beyond
the specific indications, e.g. a drug like Fosomax was not
only presented as a bone density builder but as a
breakages preventer [15].
The strategy proved to be successful for the pharma-
ceuticals. Patient and consumer organizations were
powerful allies for pressuring the Congress for regulatory
changes needed by the pharmaceutical industry [14].
Patient associations have demonstrated to be good allies
in pressuring for approvals of new drugs and for classify-
ing new diseases and conditions to become recognized,
and consequently, to be reimbursed by private and
employer-based health plans and public programs.
Patient testimonies have been very useful in convincing
the FDA scientific reviewers to approve new drugs,
despite the fact that in some cases serious concerns
about drug safety existed. Also these groups have been
very instrumental in pressuring reticent physicians to
prescribe drugs for off-label uses. In the U.S., pharmaceu-
tical companies cannot promote off-label use of their
products but can inform physicians about them. Patients,
well trained by the industry, are the best way to create
the demand for these off-label treatments [16]. Patient
advocacy organizations that offer lists of physicians to
patients and also recommend treatments become power-
ful allies of the pharmaceutical industry [14].
Awareness campaigns and health fairs in school and
community settings also are tools that the companies
have utilized since the middle of 1990s. In 1994, Eli Lily
sponsored a National Depression Awareness Day in a
Maryland high school, reaching 1,300 students [14].
Other companies followed this initiative on college cam-
puses. The awareness campaigns commonly go a step
further by promoting the use of the drugs that the spon-
sor makes. More importantly, they market the condition,
teaching about very general signs and symptoms that
mobilize people to request medical help [16]. For their
awareness campaigns, as well as for television shows,
ads, and other types of promotions, the companies also
contract celebrities to talk to the public about their
struggles against some diseases and how medications
have helped them to live successful lives [16,26]. Health
fairs in community settings also offer a good opportu-
nity to expand the number of potential consumers of
pharmaceutical products. Companies offer free tests for
cholesterol, diabetes, high blood pressure, etc. and infor-
mation about these diseases/conditions. Another inter-
esting way that pharmaceutical companies use to create
awareness of diseases and treatments is to post commu-
nication tools on their websites to facilitate the “dialo-
gue between physicians and patients.” Some tools are
for patients and others for physicians [27].
Pharmaceutical companies create new tools to facili-
tate the identification of potential consumers of their
drugs. Short questionnaires to test the risk for diseases/
conditions are available in magazines, as well as at web-
sites of pharmaceutical companies, patient associations,
and associations for specific diseases (e.g. American Dia-
betes Association) [26,28]. Moreover, pharmaceutical
companies also send questionnaires by mail to potential
consumers with information about specific drugs. Addi-
tionally, these questionnaires are available in primary
care settings and schools. The questionnaires contain a
few general questions about common signs and symp-
toms. Depending on the amount of positive answers, the
respondent is recommended to consult with a doctor.
Despite the fact that the test may conclude that a per-
son is not at risk, the recommendation is that he/she
should learn more about the disease/condition because
the questionnaire may not have evaluated all risks [28].
Some pharmaceutical companies fund cable television
channels dedicated solely to provide health information.
Special programs and the technology to watch them are
offered free to hospitals and have been installed in
patient areas. The programs combine specific informa-
tion with ads and logos of the company that sponsor
them [16]. Moreover, health news segments and health
information on television are also new ways to inform
consumers about research findings or to create awareness
of diseases/conditions and the availability of treatments.
Pharmaceutical companies produce this information that
is then offered free of charge to the media [29].
Other companies created subsidiaries to develop dis-
ease management services for managed care organiza-
tions and big employers that manage their own health
insurance plans, such as Ford and General Motors [14].
The service consists in providing the health plan mem-
bers with state-of-the-art information about disease/con-
ditions and how to maintain medication compliance.
The websites also offer tools to engage patients on
healthy behaviors, such as exercise and nutrition. The
sites provide people with health toolboxes that allow
them to register doctor appointments, medication times,
and medication renewal dates. The websites would then
prompt patients to comply with their treatments and
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check other biological and behavioral indicators (blood
pressure, weight, nutrition, physical activities, among
others), and to enter the data to monitor improvements.
These databases provide manager companies a large
quantity of information about demographic profiles of
how certain patients are prescribed, use medications,
and other health data. Companies are able to perform
sophisticated data mining to understand patient and
physician behavior in regards to a specific health pro-
blem or condition and consequently develop more pre-
cise promotion of their drugs. For Merck, a pioneering
company in developing this type of information manage-
ment capabilities, sales increased 23% in 2000. The sub-
sidiary created by Merck, Medco, managed the
pharmaceutical benefits of 51 million Americans in this
year [14].
In the following years, free and paid websites of this
kind flourished, especially for chronic diseases, lifestyle
conditions, and mental health disorders. Subscriptions
to these websites opened the doors for multiple compa-
nies and organizations (not only pharmaceuticals) to
send information about diseases/conditions, and to pro-
mote drugs, diet products, medical procedures, etc. The
worldwide capability of these tools allows companies to
operate beyond the geographical boundaries and avoid
regulations in place in specific countries.
Discussion
Biomedicalizing life to regain the hegemony of the health
sector
In previous sections we analyzed the strategies utilized
by the pharmaceutical industry to regain market posi-
tions and leadership in defining the health-ill-care pro-
cess in the U.S. From the U.S., multinational companies
export, through their subsidiaries in other countries, to
the rest of the world their new business models and
strategies to regain market power. Models and strategies
that the companies modify accordingly with the health
sector organization and the regulatory environment in
each country. Next we will consider some concepts
from social sciences theories to better understanding the
deep implications of these strategies for the lives of
people.
Medicalization is a concept developed in the 1970s to
define aspects of life as medical problems previously
outside of the jurisdiction of medicine [30-32]. Profound
transformations in medicine, facilitated by advances in
technosciences, started in the 1980s. To understand
these transformations Clarke et al. developed the con-
cept of biomedicalization, based on Foucault’s theory of
biopower and later developments by Rainbow [9]. While
medicalization focused on illnesses, rehabilitation, and
care; biomedicalization focuses on health as an interna-
lized moral mandate of self-control, surveillance, and
transformation. Advances in biomedical technosciences,
such as molecular biology, genomization, medical diag-
nostic and treatment technologies, as well as computer
and communicational developments created the possibi-
lities for radicalizing the medicalization. Biomedicaliza-
tion implies a “shift from enhanced control over
external nature (i.e. the world around us) to the harnes-
sing and transformation of the internal nature (i.e. biolo-
gical processes of human and non-human life forms),
often transforming life itself” (p. 164) [9]. Biotechnolo-
gies, including drugs and other devices available to
patients/consumers, create new biomedicalized subjec-
tivities, identities, and biosocialities. New forms of social
relationships are constructed around and through such
identities (p. 165) [9]. Examples of these kind of new
forms of social relationships are the social networks
using websites, blogs, and other internet forums dedi-
cated to health issues. It is important to remark that
these new identities do not always imply the acceptance
of the biomedicalized discourses and practices: some of
these forum/groups are questioning the moral mandate
and other forms of biomedicalization [33]. The process
is not unidirectional and different discourses are created
by a multiplicity of individuals and organizations. New
organizational developments and regulatory measures
could transform the current situation.
The transformation of medicalization into biomedicali-
zation required the confluence of several processes in
which the financialization of the health sector had an
important role. This process increased exponentially the
corporatization of the sector and the commodification
of their products at different levels: provision, research,
and education. These changes mobilized others stake-
holders such as the pharmaceutical industry to develop
new strategies. Some of these strategies, as we analyzed
previously, included enhancing the direct relationship
with potential clients of health products (diagnostic pro-
cedures and treatments), as well as health promotion
and prevention programs and services.
The technoscientific medicine and its subfields, such
as public health, have developed illusory discourses in
which death not only could be postponed, but also pre-
vented [20]. The dream of being eternally young with
plenty of energy penetrated all social, gender and age
groups. In order to obtain this goal, the message is that
people should exercise strict control and surveillance
over the risks that could threaten their lives. Moreover,
the messages about health-ill-care are presented as
social/moral mandates, meaning that if individuals are
not proactively controlling their health, the results of
their behaviors are at a great cost to society. This goes
beyond using specific medical interventions to recover
health from illnesses or diseases; it supposes the biome-
dicalization of health promotion and prevention,
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requiring the internalization of the social mandate of
being healthy, and of surveillance practices at the indivi-
dual level.
To be healthy in the context of biomedicalization
implies that it is each individual’s responsibility to test
for diseases/conditions, and to utilize drugs, devices, and
other technomedical products and services to control
the risk of developing diseases or aggravating a condi-
tion. The services to accomplish the social/moral man-
date include internet tools and other communicational
mechanisms that introduce information through the
intimacy of personal computer, home entertainment
devices, as well as school and other small environments.
Individuals are taught about diseases/conditions, how to
test for them, and how to access services and products
to preserve their health.
In the context of biomedicalization health professionals,
in their traditional role as leaders of the process of cure or
alleviation of disease, are more and more dispensable for
the new business model developed by the pharmaceutical
industry. As we described previously the advances in com-
puterization and data banking facilitate the capture, sto-
rage, and analysis of enormous amounts of data from
individuals. All of this information is utilized to generate
messages to reach millions of people interested in health
issues. The communication strategies can be developed
considering differences in social classes, ages, genders,
nationalities, cultures/ethnicities, diseases/conditions/risks,
and so forth. There are numerous products and services
that the pharmaceutical industry promotes under the con-
cept of “educating people” to prevent the risks of becom-
ing ill that do not require health provider mediation for
their consumption. Also, we have described previously
that pharmaceutical companies developed tools to teach
patients how to direct their physicians and other health
professionals to prescribe the desired product. Young peo-
ple are especially vulnerable to these kinds of marketing
messages that promote self-diagnosed and self-prescribed
behaviors [21,22].
The concept of biopedagogy is also useful to comple-
ment the understanding of the analyzed phenomena.
This concept, drawing from Foucault’s biopower theory,
is described by Wright as the normalizing and regulating
practices traditionally reserved to schools, but currently
appropriated by other learning and communicational
spaces, and disseminated more widely through the web
and other forms of media [34]. Biopedagogies place indi-
viduals under constant surveillance and towards
increased self-monitoring by elevating their knowledge
around diseases/conditions, as well as learning how to be
healthy. Using Berenstein, Wright states that we are now
living in “totally pedagogized societies” where methods to
evaluate, monitor and survey the body are encouraged
across a range of cultural practices (p.8) [35].
Individuals are offered a number of ways to under-
stand and change their behaviors, as well as encouraged
to take action to educate other members of their
families and communities to have healthy lives. Most of
the pedagogical tools are created to govern bodies and
to provide the social meanings by which individuals
come to know themselves and others but not the social-
political environment. Moreover the scientific truths are
recontextualized in different social and cultural sites to
inform and persuade people on how they should under-
stand their bodies and how to live their lives. In this
light, health information is developed to facilitate the
incorporation of the “outside” world (the social and eco-
nomic wellbeing of others) into the “inside” (psyche and
body) of the individual (p 49) [36].
In principle more access to medical and health knowl-
edge and information could be considered democratic
and it needs to be welcomed. However, in practice we
should critically analyze how the data is created, by
whom, and what are the interests behind this information
market. In addition, the commodification of this process
in capitalist societies implies that the access to informa-
tion is stratified, non-democratic, and differentially
affecting social groups and countries. People from the
lower classes receive messages reinforcing the social/
moral mandate to control their health in order that they
do not become a burden to society. For these populations
the biopedagogies are implemented at schools, health
fairs, community events, and media (especially televi-
sion). Well intentioned professionals working for public
health agencies, schools, and non-governmental organi-
zations also reproduce these messages and biopedagogies
without understanding how they operate and the conse-
quences for the biomedicalization of life. People will use
their limited income in testing for glucose, cholesterol,
high blood pressure, and other conditions and accessing
treatments (conventional or alternative) to control these
risks. However, as we can observe in health statistics, dis-
advantaged groups will fail to reach the healthy outcomes
of the upper classes, instead they will be left with the
guilt of not eating healthy, exercising, and having non-
stressful lives. The messages hide that most of the health
problems of these groups are not caused by their bad
genes triggered by inadequate lifestyle habits, but by the
unequal distribution of wealth.
Judicialization of health policies in Brazil: a new path on
the creation of the health consumer?
In this section, we will introduce the research that we
are initiating in Brazil to investigate if the processes of
capturing the demand side are operating through the
judicialization of health policies and how they are affect-
ing the capacity of the governmental administrations to
regulate the health sector.
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The importance of understanding if the judicialization
of the health policies in Brazil is another strategy that
the pharmaceutical industry is using to regain market
power resides in two important facts: 1) in this country
health is considered a common good not a private one;
and 2) the governmental agencies led the regulatory
process in a public-private environment of health care
service provision. Brazil approved in 1988 a constitu-
tional amendment declaring that health is a right that
the state must guarantee and that each Brazilian has the
right to universal and integral access to health care. The
constitutional nature of the right to health opens the
option for citizens to utilize the judicial branch to
demand the fulfillment of their rights when they believe
that the constitutional mandate is not followed.
Most of the health care services under the Brazilian
Unified Health System (UHS) are offered through an
extensive network of public primary care clinics and
hospitals, as well as public health programs managed by
municipalities. Brazilian citizens also have the right to
receive health care services, paid with public funds,
through private providers, if the public system does not
offer the needed services. In part, because this private-
public arrangement to guarantee the constitutional right
to universal access to health, the public system is
confronting increasing costs not matched by sufficient
budget allocations. This obligates governmental adminis-
trators to deny access to some health care services and
put limitations on the kind of services that can be pro-
vided. In particular, these limitations affect specialized
and costly treatments, most of which are offered by the
private sector. By appealing to the constitutional right,
an increased number of individuals are interposing judi-
cial claims demanding that the public system covers
health care services that their physicians recommend to
them.
Data from the Superior Tribunal of Justice in Brazil
indicate that in 2001 only two claims related to health
issues were interposed. However, by 2004 the number of
cases increased to 672 [37]. The Health Secretary of Rio
de Janeiro started recording the numbers of judicial
claims in 1991. Since then and until 1999, the number
of cases slowly increased, especially in relation to some
diseases. Starting in 2000, the number of cases requiring
the Justice to obligate the state to pay for procedures to
treat different health problems denied by public medical
institutions increased exponentially. At the end of 2002,
the Health Secretary counted 2,733 judicial actions
against the State of Rio de Janeiro. In March 2006 the
number of claims rose to 7,758 [38].
In the majority of cases, the judges ruled in favor of the
citizens, obligating the public health system to pay for the
demanded services [39]. To include more medications,
diagnostic procedures, and treatments to be paid by the
public system is in accordance with the constitutional rule
to guarantee the health right, but it creates a conflict
between the health and the judicial systems. Officials from
health agencies consider that the judicial branch is assum-
ing authority for decisions that need to be made by health
specialists. They complain especially when the solicited
medications, treatments, or diagnostic procedures are
new, experimental, or off-label indications, implying that
the efficacy and safety are not well established.
The judicial branch is playing a more central role in
defining the health policies by focusing only on the con-
stitutional right. But this branch of the government may
not be considering the powerful actors that could be
using the justice system to mandate the inclusion of
new treatments to be paid by the UHS. Moreover,
increasing the number of services provided with limited
funding allocation may threaten the constitutional right
itself. Fewer people may be accessing basic needed ser-
vices, favoring only small numbers of people that receive
costly specialized treatments. In addition, if the treat-
ments the judicial system mandates the UHS to pay are
predominantly those offered by private providers, the
public system is subsidizing them, when public hospitals
and clinics are confronting increasing budgetary restric-
tions. In fact, the judicial claims appear to benefit more
the middle and upper classes. A study analyzing 2,927
judicial claims demanding the state of São Paulo to pay
for medications not covered by the UHS, shows that
73% of claimants reported that they live in high and
middle income neighborhoods, while only 27% live in
low income areas. Moreover, 74% of the cases were
represented by private lawyers while only 26% were
represented by public defenders [39].
These are the nature of the problems that our team is
starting to investigate in Brazil. Our empirical work will
focus on understanding the implications for regulatory
agencies of the judicialization of the health sector, as
well as the role that the medical industrial complex
plays in this process. We are also studying if the Brazi-
lian pharmaceutical industry is adapting the strategies
observed in the U.S. which turns users/patients into
consumers by marketing new treatments, e.g., those
approved but not covered by the public system, off-label
indications, or not approved at all by the regulatory
agencies in Brazil. In situations like Brazil where health
is a right guaranteed by the constitution, unneeded con-
sumerism of health services promoted by the medical
industrial complex may be seriously threatening the sta-
bility and continuity of the public health care system, as
well as increasing health inequities. We are only at the
beginning of this research agenda that will provide
important information to improve the regulation of the
health sector and demonstrate the need for a close dia-
logue among branches of the government.
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Conclusions
In this article we have analyzed how the leading force in
the biomedicalization process –the pharmaceutical
industry– has developed strategies to increase their
share of the health market. The dispute for the hege-
mony of the health sector between financial companies
and the medical industrial complex has deeply trans-
formed the sector. The big contenders (financial and
industrial capital) obtained a part in the distribution of
the market and economic surpluses. Public systems and
employer-based insurances, as well as health workers
(professionals and non-professionals), and moreover the
people, are those affected by the transformations. The
regulation of the sector had become largely complex.
We are in the presence of an intense process of control
and regulation of bodies “from inside out” as a type of
biomedical governance (p.181) [9]. Patients converted
into consumers are exposed to the biomedicalization of
their lives helped by the biopedagogies that operate
through subtle mechanisms which present information
as objective and created to empower consumers. Regula-
tory agencies in developed and developing countries lag
behind in their capacity to regulate data gathering and
communication tools that the multinational corpora-
tions are creating to directly reach the population.
However, it is important to remark that we consider
biomedicalization as a contradictory process that arose
as part of intercapitalistic disputes and has multiple
allies and opponents. The powerful forces that create
biomedicalized discourses operate in a situation where
other discourses try to deterritorialize, desestratify, and
create “lines of flight” opening the possibility for new
situations to emerge [40]. Our intention in analyzing the
process is to contribute to the multiplication of more
democratic voices.
We recognize that the medical model dominated by
the technosciences is not the only one operating around
the world. Other models, more centered on the needs of
the patients than on the consumption of technical pro-
cedures, are also operating and disputing the conceptua-
lization of the health-ill-care model. It is especially true
for countries such as Brazil, with a successful recent his-
tory of creating a public health care system to guarantee
the right to health of its population. However, we also
observe that the interests linked to the biomedical
model based on technosciencies are pressuring the regu-
latory agencies to change the model so that these inter-
ests can regain power. Efforts to improve the regulation,
as well as new mechanisms, should be developed.
Numerous researchers and activists are creating and
spreading useful information for people making
informed decisions about their health and to discrimi-
nate between their individual problems and those
generated by the organization of societies. The analysis
of judicialization of health policies, as we are observing
in Brazil, could help to understand the extension and
complexity of the problem and help to create a dialogue
between professionals working in health and judicial sys-
tems. Public institutions should generate and distribute
scientific, non-biased health information and alert the
population about the biased websites and other sources
of data gathering and information spreading that are
paid by private groups to pursue their commercial inter-
ests. The regulation of this type of communication and
the means to transmit the messages should be strength-
ened, but it will require a profound and broad debate
within each country. Regulating information is a delicate
matter. Regulation could be a good instrument to pro-
tect the people from spurious commercial interests, but
also it could be used to decrease the voices that oppose
the biomedicalization. Councils integrated with mem-
bers from community groups, professional associations,
health advocate organizations, among others, could be a
tool to advise and control governmental regulatory
agencies. Professional and consumer associations, pub-
licly funded and supervised, could increase the amount
of non-biased information. All efforts need to have the
objective to increase the visibility of discourses defend-
ing the individual and collective right to live healthy
lives non-governed by self-surveillance and consumption
of bioproducts, but more connected with the need to
collectively improve working and living conditions.
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